U.S. Markets closed

Sucampo Pharmaceuticals, Inc. (SCMP)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
10.25-0.25 (-2.38%)
At close: 4:00PM EDT
People also watch
  • webcast its corporate presentation at the Bank of America Merrill Lynch 2017 Health Care Conference on Thursday, May 18th at 08:00 AM Pacific Time.
  • So we issued $300 million of convertible debt in December - opening the door for the hedge funds to short the stock down 40% or more than $300 million today - so that we can buy a drug that will start to generate revenue in 2019. CFO here is not good.
  • PR time is coming per today's call on VTS-270:
    "It’s under discussions and then what that needs to include is under discussion. Obviously, in the Phase 1, 2 trial which will be coming out in publication in a couple of months, there was a physician score but I don’t want to go further down that, because I don’t want to influence potential discussions with the FDA."
  • no insider buying
  • rock star eps last qtr good luck tomorrow upside limited so i plan to sell get back to div investing. a waste of my time. never thought i needed a stop on a Zacks strong buy
  • revenue up 19%
  • I don't see a lot of risk in the purchase of Vtesse. VTS-270 looks easily approvable, possibly early. Based on prevalence and probable treatment cost, the acquisition makes sense.
  • Alpha fund is like Russian roulete over 3% 20+ right down
  • Mgmt now what's free shares for lousy performance. I vote NO all around
  • ER surprise is in the plate. The SP pressure will drive the management to do something about the valuation.
  • Strong support at $9. Not going below that. This is a great entry point for new investors. $400m market cap with $200m revenues and pipeline in late stages of development. You cannot beat that. Stock is way too oversold.
  • Got a great report from http://thesubwaytrader.com/?s=SCMP about $SCMP. I did have to subscribe but it was worth the time. Thank you guys for the tip! The chi factor: quantity=1/quality; or Day trading trading stocks.

    The Subway Trader: Trading Stocks and Making Money
    Stock alerts from the The Subway Trader. Stock trading, making money and always looking for the next big money maker.
  • another Zacks blown call
  • Poeta pictori animae. http://dataunion.tistory.com/3170

    Sucampo Pharmaceuticals NASDAQ : SCMP Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.6 In other words, the correlation coefficient of the other stoc
  • With over 28% of the shares short, it will take over 12 days to cover those short positions. Fundamentals look solid. Some risk on the Vtesse approval next year, but looks promising. Short squeeze could pop nicely on any good news. Just need to stay put and hold through this.
  • up .14 and slipping
  • Why no big company wants to buy SCMP?
    Only 1 approved drug with revenue more than 200M and the whole company is only 450M.
  • SCMP 13 hours ago a BUY rating with average target estimate $18.5....
  • Sucampo's stock has dropped post-announcement, but analyst Mr.Donovan Jones believes this is short term, and is a buying opportunity after the share lockup expires in mid-July 2017
  • 2015 Zacks hyped this a strong buy to immediately fall soon to soon be 7. Criminal Zacks had an interest to misguide